Pharmafile Logo
Pharmafocus logo
Advanced Search
Eli Lilly chief executive John Lechleiter

Lilly chief issues warning on UK reforms

February 11, 2011
Research and Development, Sales and Marketing John Lechleiter, US health reforms, healthcare reform, lilly, patent box, value-based pricing

Lilly chief executive John Lechleiter has warned that two key UK initiatives could fall seriously short of encouraging investment in …

News

Innovation is being stifled – Lilly chief executive

February 10, 2011
Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly

Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …

News
Blog footer

Digital Pharma: This is how pharma is using digital

February 10, 2011
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Android, Digital Pharma blog, Facebook, Twitter, disease awareness campaigns, ipad, iphone, social media

Pharma’s use of digital tools, from mobile apps to online campaigns to social media channels, is increasing all the time …

Feature

Amarin expands US operations

February 10, 2011
Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol

Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …

News
GSK's swine flu vaccine Pandemrix

WHO wants narcolepsy link with swine flu vaccine investigated

February 10, 2011
Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu

The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …

News

Dr Mikael von Euler moves to Oncos Therapeutics

February 10, 2011
Research and Development Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development

Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer. He has more than 20 …

Appointment

Alliance concerned over NHS competition reforms

February 10, 2011
Health and Social Care Bill, NHS, NHS Alliance, NHS reforms

The NHS Alliance has called on the Government to clarify major issues around the Health and Social Care Bill which …

News

Generics force Sanofi into standstill

February 9, 2011
Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics

An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …

News

Shire bags senior research execs from GSK and Abbott

February 9, 2011
Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development

Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …

News
Diabetes injection

Pharma-NHS diabetes project begins

February 9, 2011
Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working

A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …

News

Teva surges ahead

February 9, 2011
Sales and Marketing 2010 pharma results, Copaxone, Teva, Teva Pharmaceutical

Generics giant Teva enjoyed a strong year of growth in 2010, lifted by the acquisition of Ratiopharm, patent expiries of …

News

Dr Matthias joins Noxxon Pharma

February 9, 2011
Research and Development Dr Matthias Baumann, Noxxon Pharma, appointment, research and development

Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers. He joins from Focus Clinical Drug Development, …

Appointment
Advanced melanoma

Melanoma: intense competition to be the next milestone treatment

February 9, 2011
Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab

A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …

Feature

AZ-Targacept depression candidate moves into phase IIb

February 9, 2011
Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder

AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …

News

Early diagnosis key to UK cancer ambition

February 8, 2011
Cancer, NHS, NICE

A series of quality standards on cancer care is to be drawn up by NICE as part of a new …

Feature

Genzyme to divest pharma intermediates business

February 8, 2011
Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase

Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …

News

Pharmaceutical facility news in brief

February 8, 2011
Manufacturing and Production Baxter International, Famar, Lannett, Qatar Pharma, Sanofi-Aventis, Takeda Pharmaceutical Co

A round-up of news involving manufacturing facilities includes updates from Takeda, Famar/Sanofi, Qatar Pharma, Lannett and Baxter. Takeda Pharmaceutical Co …

News

Roche eyes ovarian cancer expansion for Avastin

February 8, 2011
Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer

Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …

News

Stabilitech appoints new commercial director

February 8, 2011
Manufacturing and Production Donna Hackett, Stabilitch, appointment, manufacturing and production

Donna Hackett joins stabilisation company Stabilitch as commercial director. She has 20 years pharma experience, most recently at pre-clinical, clinical …

Appointment

Teva plant in Israel cited by FDA, expands in Americas

February 8, 2011
Manufacturing and Production Corporacion Infarmasa, FDA, Peru, Teva, Teva Pharmaceutical, generics, generics manufacturing, manufacturing compliance

A manufacturing facility in Jerusalem operated by Teva Pharmaceutical failed to pass muster in an FDA inspection, prompting a warning …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026